IL-23 inhibitors may have a lower risk of paradoxical eczema in comparison to other biologics

1. Interleukin-23 inhibitors had a lower risk of developing paradoxical eczema when treated for plaque psoriasis compared to TNF inhibitors, IL-17 inhibitors and IL-12/23 2. Clinical features associated with increased paradoxical eczema risks included increasing age, history of atopic dermatitis, and history of hay fever. The risk was also lower in males. Evidence Rating Level: […]

The post IL-23 inhibitors may have a lower risk of paradoxical eczema in comparison to other biologics first appeared on 2 Minute Medicine.